ECSP14013104A - Formulaciones farmacéuticas estabilizadas de un potente inhibidor de hcv - Google Patents

Formulaciones farmacéuticas estabilizadas de un potente inhibidor de hcv

Info

Publication number
ECSP14013104A
ECSP14013104A ECIEPI201413104A ECPI201413104A ECSP14013104A EC SP14013104 A ECSP14013104 A EC SP14013104A EC IEPI201413104 A ECIEPI201413104 A EC IEPI201413104A EC PI201413104 A ECPI201413104 A EC PI201413104A EC SP14013104 A ECSP14013104 A EC SP14013104A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical formulations
control
stabilized pharmaceutical
hcv inhibitor
strong
Prior art date
Application number
ECIEPI201413104A
Other languages
English (en)
Spanish (es)
Inventor
Maria Fernanda Villagra
Jenness B Majeska
Edwin Louis Gump
Scott Pennino
Feng-Jing Chen
Mathias Braun
Carl Alan Busacca
Fenghe Qiu
Original Assignee
Sanofi Aventis Deutschiand Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013104(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschiand Gmbh filed Critical Sanofi Aventis Deutschiand Gmbh
Publication of ECSP14013104A publication Critical patent/ECSP14013104A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ECIEPI201413104A 2012-01-12 2014-08-08 Formulaciones farmacéuticas estabilizadas de un potente inhibidor de hcv ECSP14013104A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261586087P 2012-01-12 2012-01-12

Publications (1)

Publication Number Publication Date
ECSP14013104A true ECSP14013104A (es) 2015-11-30

Family

ID=47628447

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201413104A ECSP14013104A (es) 2012-01-12 2014-08-08 Formulaciones farmacéuticas estabilizadas de un potente inhibidor de hcv

Country Status (27)

Country Link
US (2) US20140037719A1 (h)
EP (1) EP2802313A1 (h)
JP (1) JP2015503616A (h)
KR (1) KR20140109433A (h)
CN (1) CN104244926A (h)
AP (1) AP2014007760A0 (h)
AR (1) AR089710A1 (h)
AU (1) AU2013208024A1 (h)
BR (1) BR112014017058A8 (h)
CA (1) CA2861041A1 (h)
CL (1) CL2014001783A1 (h)
CO (1) CO7000774A2 (h)
EA (1) EA201400808A1 (h)
EC (1) ECSP14013104A (h)
HK (1) HK1204982A1 (h)
IL (1) IL233550A0 (h)
IN (1) IN2014DN05759A (h)
MA (1) MA35865B1 (h)
MX (1) MX2014008205A (h)
NZ (1) NZ626353A (h)
PE (1) PE20141817A1 (h)
PH (1) PH12014501598A1 (h)
SG (1) SG11201404042VA (h)
TN (1) TN2014000295A1 (h)
TW (1) TW201340969A (h)
UY (1) UY34569A (h)
WO (1) WO2013106506A1 (h)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
EP2970335B1 (en) 2013-03-15 2019-05-08 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5329976A (en) * 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
UY28323A1 (es) 2003-05-21 2004-12-31 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
EP1753775B1 (en) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Process for preparing acyclic hcv protease inhibitors
WO2006130552A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
EA018603B1 (ru) 2008-09-16 2013-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
SI2358355T1 (sl) * 2008-11-21 2014-02-28 Boehringer Ingelheim Gmbh Farmacevtski sestavek potentnega inhibitorja HCV za oralno dajanje
PL2451438T3 (pl) 2009-07-07 2014-07-31 Boehringer Ingelheim Int Kompozycja farmaceutyczna inhibitora proteazy wirusowego zapalenia wątroby typu C

Also Published As

Publication number Publication date
PH12014501598A1 (en) 2014-10-08
AU2013208024A1 (en) 2014-07-10
IL233550A0 (en) 2014-08-31
EP2802313A1 (en) 2014-11-19
NZ626353A (en) 2016-02-26
KR20140109433A (ko) 2014-09-15
BR112014017058A2 (pt) 2017-06-13
US20150190458A1 (en) 2015-07-09
MA35865B1 (fr) 2014-12-01
US20140037719A1 (en) 2014-02-06
TW201340969A (zh) 2013-10-16
CO7000774A2 (es) 2014-07-21
CL2014001783A1 (es) 2014-12-12
MX2014008205A (es) 2014-08-08
CA2861041A1 (en) 2013-07-18
EA201400808A1 (ru) 2015-02-27
CN104244926A (zh) 2014-12-24
AP2014007760A0 (en) 2014-07-31
JP2015503616A (ja) 2015-02-02
HK1204982A1 (en) 2015-12-11
PE20141817A1 (es) 2014-12-17
TN2014000295A1 (en) 2015-12-21
UY34569A (es) 2013-07-31
SG11201404042VA (en) 2014-08-28
IN2014DN05759A (h) 2015-04-10
WO2013106506A1 (en) 2013-07-18
AR089710A1 (es) 2014-09-10
BR112014017058A8 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
ZA201802657B (en) Crystal forms of beta-nicotinamide mononucleotide
PH12017500858A1 (en) Mocrocyclic peptides useful as immunomodulators
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12018500284A1 (en) 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
BR112017007636A2 (pt) métodos para a preparação de ribosídeos
DK3133068T3 (da) Amidderivater og farmaceutisk acceptable salte deraf, fremgangsmåde til fremstilling deraf og medicinske anvendelser deraf
IL252477B (en) History of 2-[(ethenyl-carbonyl-amino)anilino]-pyrimidine, process for their preparation and pharmaceutical preparations containing them
MY192824A (en) Compound targeting il-23a and tnf-alpha and uses thereof
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
SG11201502522WA (en) 1,2,4-triazine derivatives for the treatment of viral infections.
IL242468B (en) A method for stabilizing suspensions of red blood cells encapsulating an active substance, the resulting suspension
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
IL251770B (en) Granules of an active substance with a double taste masking technique, a method for their production and orally disintegrating tablets containing them
MY191081A (en) Compound targetting il-23a and b-cell activating factor (baff) and uses thereof
MX385925B (es) Oritavancina de alta pureza y método para producir la misma.
MY197524A (en) System of multiple bags and method for the preparation of hemocomponents
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
ECSP14013104A (es) Formulaciones farmacéuticas estabilizadas de un potente inhibidor de hcv
MD4763B1 (ro) Compoziţie farmaceutică
CY1120192T1 (el) Ενωσεις για την ενισχυση της γνωστικης λειτουργιας
FR3001158B1 (fr) Capsules gelifiees, et capsules gelifiees lyophilisees, renforcees, contenant des nano-objets et leurs procedes de preparation.
IN2014DN07897A (h)
TH1301000018B (th) รูปผลึกเดลตาของเกลืออาร์จินีน (arginine) ของเพอรินโดพริล (perindopril), กระบวนการสำหรับการเตรียมสารดังกล่าว และองค์ประกอบทางเภสัชกรรมที่มีสารดังกล่าว
IN2014MU00077A (h)